Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of Moderate Buy by Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective […]

Related Keywords

China ,Arizona ,United States ,America ,Piper Sandler ,Stifel Nicolaus ,Quest Partners ,Kymera Therapeutics Company Profile ,China Universal Asset Management Co ,Jpmorgan Chase Co ,Venture Fund Xlp Atlas ,Nasdaq ,Hsbc Holdings ,Securities Exchange Commission ,Allspring Global Investments Holdings ,Kymera Therapeutics Inc ,Kymera Therapeutics ,Get Free Report ,Venture Fund ,Exchange Commission ,Director Bruce Booth ,Global Investments Holdings ,State Retirement System ,Universal Asset Management ,Get Free ,Kymera Therapeutics Daily ,Nasdaq Kymr ,Kymr ,Medical ,Ratings ,Consensus ,